7 Results for "

serum potassium elevation

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "serum potassium elevation" in MCE Product Catalog:

Cat. No.: HY-W145486
CAS No.: 299-28-5
Calcium gluconate is an orally effective calcium salt supplement . Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury .
loading...
    loading...
Cat. No.: HY-113526
CAS No.: 100557-04-8
AR-12463 is a derivative of Trapidil (HY-B1016). AR-12463 inhibits the conversion of [14C]acetate to cholesterol. AR-12463 significantly reduces the elevation of total cholesterol in rabbit serum and prevents cholesterol incorporation into tissues. AR-12463 can be used to study atherosclerosis.
loading...
    loading...
Cat. No.: HY-19242
CAS No.: 156579-02-1
Target:  

Antifolate

Research Areas:  

Inflammation/Immunology

MX-68 is an orally active antifolate agent. MX-68 can prolong the lifespan of MRL/lpr mice, delay the onset of proteinuria, and inhibit the elevation of serum blood urea nitrogen and cholesterol levels. MX-68 is also an anti-rheumatic agent, which exerts potent antiproliferative effects on rheumatoid arthritis-related cells and can inhibit arthritis in rats. MX-68 can be used in the research of autoimmune diseases such as autoimmune kidney disease and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-170919
CAS No.: 3025799-28-1
Target:  

FGFR

Research Areas:  

Cancer

FGFR2/3-IN-2 (compound 10) is an orally active FGFR2 and FGFR3 inhibitor. FGFR2/3-IN-2 inhibits FGFR2 and FGFR3 with IC50s of 3.7 nM and 31.2 nM (preincubation time 1 h), respectively. FGFR2/3-IN-2 spares FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo. FGFR2/3-IN-2 induces tumor stasis or regression in the SNU-16 gastric cancer model .
loading...
    loading...
Cat. No.: HY-181077
Target:  

AMPK

Research Areas:  

Endocrinology

AMPKα1 activator 1 is a selective and orally active AMPKα1 activator with an EC50 of 35.1 nM. AMPKα1 activator 1 shows 176-fold selectivity over AMPKα2. AMPKα1 activator 1 can be used as a cell protectant and a kidney protectant. AMPKα1 activator 1 attenuates elevation of serum creatinine and blood urea nitrogen levels, alleviates kidney damage, and reduces cellular infiltration in renal ischemia-reperfusion injury contexts. AMPKα1 activator 1 can be associated with renal ischemia-reperfusion injury research .
loading...
    loading...
Cat. No.: HY-182046
CAS No.: 2930131-74-9
HD202A is an orally active, selective dual inhibitor of MNK1/MNK2 (with IC50 values of 6.09 nM and 8.06 nM, and Kd values of 1.913 μM and 5.244 μM, respectively) that inhibits the MNK-eIF4E signaling pathway. By downregulating perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α, HD202A enhances mitochondrial fatty acid oxidation and redox homeostasis. HD202A effectively suppresses body weight gain, hepatic lipid accumulation and elevation of serum lipids, significantly improves glucose tolerance and insulin sensitivity of the organism, and ameliorates inflammatory features. With these comprehensive pharmacological activities, HD202A exhibits great application potential in studies of metabolic dysfunction-associated steatotic liver disease .
loading...
    loading...
Cat. No.: HY-P992072

Target:  

Apoptosis Caspase

Research Areas:  

Metabolic Disease

Anti-Human/Mouse CD95 Antibody (HFE7A) is an antibody targeting human/mouse Fas (CD95), with a Kd of 1.6 nM in mice. Anti-Human/Mouse CD95 Antibody (HFE7A) modulates the Fas-mediated apoptotic signaling pathway without blocking the binding of Jo2 to Fas. Anti-Human/Mouse CD95 Antibody (HFE7A) inhibits Jo2-induced caspase activation, mitochondrial depolarization, hepatocyte death and apoptosis. Anti-Human/Mouse CD95 Antibody (HFE7A) protects BALB/c mice against Jo2-induced acute liver injury and reduces Jo2-associated elevation of serum transaminase levels. Anti-Human/Mouse CD95 Antibody (HFE7A) can be used in studies related to liver injury. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977) .
loading...
    loading...